指南与共识神经PETCT

痴呆脑PET/CT成像ACR-ACNM-ASNR-SNMMI实践参数更新

ACR-ACNM-ASNR-SNMMI Practice Parameter for the Performance of Brain PET/CT Imaging in Dementia.
指南 / 共识 · AJNR Am J Neuroradiol · 2026-02-03

该实践参数由ACR、ACNM、ASNR与SNMMI联合修订,更新纳入所有FDA批准的痴呆PET显像剂。文件旨在规范痴呆PET/CT的临床适应证、人员资质与技术规格,支持对认知衰退背后神经退行性过程的更早期、更准确诊断。

要点

  • 痴呆脑PET/CT应结合临床适应证选择FDA批准的显像剂。
  • 报告前应核对人员资质与技术操作是否满足实践参数要求。
  • 关注早期神经退行性病变的PET特征,提高诊断特征描述的准确性。

核心结论

  • 更新后的实践参数旨在为痴呆PET/CT成像的临床适应证、技术规格及人员资质提供参考。
  • 本次修订纳入了所有FDA批准的痴呆PET显像剂,并反映PET在认知衰退神经退行性过程中早期和更准确诊断的扩展作用。

研究设计与样本

  • 由ACR、ACNM、ASNR和SNMMI共同修订的实践参数文件。
  • 修订流程依据ACR网站「The Process for Developing ACR Practice Parameters and Technical Standards」进行。

诊断标准与关键数值

  • 文件纳入所有FDA批准的用于痴呆评估的PET显像剂。

临床应用与阅片要点

  • 用于痴呆患者脑PET/CT检查的临床适应证选择。
  • 用于脑PET/CT设备技术规格的日常质控与扫描方案参考。
  • 用于检查相关人员资质的科室管理与报告规范参考。

局限性

  • 原文未报告具体技术阈值、诊断准确性数值或样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM/OBJECTIVES/BACKGROUND: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Society for Neuroradiology (ASNR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI).This important update now includes all FDA approved agents for PET imaging of dementia and reflects the expanding role of PET imaging for the early and more accurate diagnostic characterization of the neurodegenerative processes underlying cognitive deterioration. Clinical indications, personnel qualifications, and technical specifications are discussed in this practice parameter.

METHODS: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters - Neuroradiology of the ACR Commission on Neuroradiology and the Committee on Practice Parameters - Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging in collaboration with the ACNM, the ASNR, and the SNMMI.

RESULTS: ACR/ACNM/ASNR/SNMMI collaborative work to update the practice parameter of Brain PET imaging. The new parameter includes all FDA approved PET agents for the evaluation of dementia.

CONCLUSIONS: The updated practice parameter is intended to serve as a reference for clinical indications, technical specifications, and personnel qualifications state for PET/CT imaging in dementia.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Tu, Esposito, Agarwal, et al. ACR-ACNM-ASNR-SNMMI Practice Parameter for the Performance of Brain PET/CT Imaging in Dementia. AJNR Am J Neuroradiol. 2026. PMID: 41506843. doi:10.3174/ajnr.A9105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。